Phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor growth and prognosis in patients with bladder cancer: correlation with matrix metalloproteinase-2 and -7 and E-cadherin

Human Pathology

Volumn 40, Issue 4, 2009, Pages 496-504

  Miyata, Yasuyoshi ^a   Sagara, Yuji ^a   Kanda, Shigeru ^b   Hayashi, Tomayoshi ^c   Kanetake, Hiroshi ^a  

^a NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION   (Japan)

^c NAGASAKI UNIVERSITY HOSPITAL   (Japan)

Author keywords

Bladder cancer; E cadherin; Hepatocyte growth factor receptor; Matrix metalloproteinases; Prognosis

Indexed keywords

BIOLOGICAL MARKER; CD44V ANTIGEN; CD44V6 ANTIGEN; GELATINASE A; INTERSTITIAL COLLAGENASE; MATRILYSIN; MATRIX METALLOPROTEINASE 14; SCATTER FACTOR RECEPTOR; UROKINASE RECEPTOR; UVOMORULIN; VASCULOTROPIN;

ARTICLE; BLADDER CANCER; CANCER CELL; CANCER STAGING; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MEDICAL RECORD REVIEW; METASTASIS; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RETROSPECTIVE STUDY; SURVIVAL; TUMOR GROWTH;

ADULT; CADHERINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 7; MIDDLE AGED; NEOPLASM STAGING; PHOSPHORYLATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MET; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 62049085386     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2008.09.011     Document Type: Article

References (35)

1. Kurth K.H., Bouffioux C., Sylvester R., van der Meijden A.P., Oosterlinck W., and Brausi M. Treatment of superficial bladder tumors: achievements and needs. The EORTC Genitourinary Group. Eur Urol 37 (2000) 1-9
2. Quek M.L., Quinn D.I., Daneshmand S., and Stein J.P. Molecular progression in bladder cancer-a current perspective. Eur J Cancer 39 (2003) 1501-1510
3. Paciucci R., Vila M.R., Adell T., et al. Activation of the urokinase plasminogen activator/urokinase plasminogen activator receptor system and redistribution of E-cadherin are associated with hepatocyte growth factor-induced motility of pancreas tumor cells overexpressing. Met Am J Pathol 153 (1998) 201-212
4. Hamasuna R., Kataoka H., Moriyama T., Itoh H., Seiki M., and Koono M. Regulation of matrix metalloproteinase-2 (MMP-2) by hepatocyte growth factor/scatter factor (HGF/SF) in human glioma cells: HGF/SF enhances MMP-2 expression and activation accompanying up-regulation of membrane type-1 MMP. Int J Cancer 82 (1999) 274-281
5. Jeffers M., Schmidt L., Nakaigawa N., et al. Activating mutations for the met tyrosine kinase receptor in human cancer. Proc Natl Acad Sci U S A 94 (1997) 11445-11450
6. Endo K., Shirai A., Furukawa M., and Yoshizaki T. Prognostic value of cell motility activation factors in patients with tongue squamous cell carcinoma. Hum Pathol 37 (2006) 1111-1116
7. Cheng H.L., Trink B., Tzai T.S., et al. Overexpression of c-met as a prognostic indicator for transitional cell carcinoma of the urinary bladder: a comparison with p53 nuclear accumulation. J Clin Oncol 20 (2002) 1544-1550
8. Sanchez-Carbayo M., Socci N.D., Lozano J.J., Haab B.B., and Cordon-Cardo C. Profiling bladder cancer using targeted antibody arrays. Am J Pathol 168 (2006) 93-103
9. Ferracini R., Longati P., Naldini L., Vigna E., and Comoglio P.M. Identification of the major autophosphorylation site of the Met/hepatocyte growth factor receptor tyrosine kinase. J Biol Chem 266 (1991) 19558-19564
10. Fixman E.D., Naujokas M.A., Rodrigues G.A., Moran M.F., and Park M. Efficient cell transformation by the Tpr-Met oncoprotein is dependent upon tyrosine 489 in the carboxy-terminus. Oncogene 10 (1995) 237-249
11. Birchmeier C., Brichmeier W., Gherardi E., and Vande Woude G.F. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4 (2003) 915-925
12. Bertotti A., and Comoglio P.M. Tyrosine kinase signal specificity: lessons from the HGF receptor. Trends Biochem Sci 28 (2003) 527-533
13. Miyata Y., Kanda S., and Kanetake H. Presence of phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor progression and survival in patients with conventional renal cell carcinoma. Clin Cancer Res. 12 (2006) 4876-4881
14. Inoue T., Kataoka H., Goto K., et al. Activation of c-Met (hepatocyte growth factor receptor) in human gastric cancer tissue. Cancer Sci. 95 (2004) 803-808
15. Murai M., Shen X., Huang L., et al. Over expression of c-met in oral SCC promotes hepatocyte growth factor-induced disruption of cadherin junctions and invasion. Int J Oncol 24 (2004) 831-840
16. Recio J.A., and Merlino G. Hepatocyte growth factor/scatter factor induces feedback up-regulation of CD44v4 in melanoma cells through Egr-1. Cancer Res 63 (2003) 1576-1582
17. Puri N., Khramtsov A., Ahmed S., et al. A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts. Cancer Res 67 (2007) 3529-3534
18. Gontero P., Banisadr S., Frea B., and Brausi M. Metastasis markers in bladder cancer: a review of the literature and clinical considerations. Eur Urol 46 (2004) 296-311
19. Nicholson B.E., Frierson H.F., Conaway M.R., et al. Profiling the evolution of human metastatic bladder cancer. Cancer Res 64 (2004) 7813-7821
20. Peruzzi B., and Bottaro D.P. Targeting the c-Met signaling pathway in cancer. Clin Cancer Res 12 (2006) 3657-3660
21. Chattopadhyay C., El-Nagger A.K., Williams M.D., and Clayman G.L. Small molecule c-MET inhibitor PHA665752: effect on cell growth and motility in papillary thyroid carcinoma. Head Neck 30 (2008) 991-1000
22. Michael M., Babic B., Khokha R., et al. Expression and prognostic significance of metalloproteinases and their tissues inhibitors in patients with small-cell lung cancer. J Clin Oncol 17 (1999) 1802-1808
23. Kallakury B.V.S., Karikehalli S., Haholu A., et al. Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin Cancer Res 7 (2001) 3113-3119
24. Leinonen T., Pirinen R., Böhm J., Johansson R., Ropponen K., and Kosma V.M. Expression of matrix metalloproteinases 7 and 9 in non-small cell lung cancer. Relation to clinicopathological factors, β-catenin and prognosis. Lung Cancer 51 (2006) 313-321
25. El-Kott A.F., Khalil A.M., and EL-Kenawy A.E.L.M. Immunohistochemical expression and its receptor uPAR and their prognostic significant in urinary bladder carcinoma. Int Urol Nephrol 36 (2004) 417-423
26. Zhang Z., Xie D., Li X., et al. Significance of TWIST expression and its association with E-cadherin in bladder cancer. Hum Pathol 38 (2007) 598-606
27. Lipponen P., Aaltoma S., Kosma V.M., Ala-opas M., and Eskelinen M. Expression of CD44 standard and variant-v6 proteins in transitional cell bladder tumours and their relation to prognosis during a long-term follow-up. J Pathol 186 (1998) 157-164
28. Kurahara H., Takao S., Maemura K., Shinchi H., Natsugoe S., and Aikou T. Impact of vascular endothelial growth factor-C and -D expression in human pancreatic cancer: its relationship to lymph node metastasis. Clin Cancer Res 10 (2004) 8413-8420
29. Cheng H.L., Liu H.S., Lin Y.J., et al. Co-expression of RON and MET is a prognostic indicator for patients with transitional-cell carcinoma of the bladder. Br J Cancer 92 (2005) 1906-1914
30. Ide T., Kitajima Y., Miyoshi A., et al. Tumor-stromal cell interaction under hypoxia increases the invasiveness of pancreatic cancer cells thorough the hepatocyte growth factor/c-Met pathway. Int J Cancer 119 (2006) 2750-2759
31. Kermorgant S., Aparicio T., Dessirier V., Lewin J.M.L., and Lehy T. Hepatocyte growth factor induces colonic cancer cell invasiveness via enhanced motility and protease overproduction. Evidence for PI3 kinase and PKC involvement. Carcinogenesis 22 (2001) 1035-1042
32. Sawada K., Radjabi A.R., Shinomiya N., et al. c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res 67 (2007) 1670-1679
33. Varro A., Kenny S., Hemers E., et al. Increased gastric expression of MMP-7 in hypergastrinemia and significance for epithelial-mesenchymal signaling. Am J Physiol Gastrointest Liver Physiol 292 (2007) G1133-G1140
34. Davies G., Jiang W.G., and Mason M.D. Cell-cell adhesion molecules and their associated proteins in bladder cancer cells and their role in mitogen induced cell-cell dissociation and invasion. Anticancer Res 19 (1999) 547-552
35. Laprise P., Langlois M.J., Boucher M.J., Jobin C., and Rivard N. Down-regulation of MEK/ERK signaling by E-cadherin-dependent PI3K/AKT pathway in differentiating intestinal epithelial cells. J Cell Physiol 199 (2004) 32-39